+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
AVIENCE

Avience Biomedicals Share Price

 

 

Avience Biomedicals live price: ₹414.95.

Avience Biomedicals Performance

  • Today's Low
  • ₹395
  • Today's High
  • ₹415
  • 52 Week Low
  • ₹395
  • 52 Week High
  • ₹415
  • Open Price₹395
  • Previous Close₹0
  • Volume726,000
  • 50 DMA-
  • 100 DMA-
  • 200 DMA-

Avience Biomedicals Chart

Investment Returns

  • Over 1 Month + 99.5%
  • Over 3 Month + 99.5%
  • Over 6 Month + 99.5%
  • Over 1 Year + 99.5%

Smart Investing Starts Here Start SIP with Avience Biomedicals for Steady Growth!

Invest Now

Avience Biomedicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 167
  • P/B Ratio
  • 7.3
  • Average True Range
  • -
  • EPS
  • 13.06
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • -
  • MFI
  • -

Avience Biomedicals Financials

Avience Biomedicals Technicals

EMA & SMA

Current Price
₹414.95
+ 206.95 (99.5%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • -
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

408.37 Pivot Speed
  • R3 441.28
  • R2 428.12
  • R1 421.53
  • S1 401.78
  • S2 388.62
  • S3 382.03

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

N/A

Group Rank

Avience Biomedicals Shareholding Pattern

No data available.

Avience Biomedicals FAQs

Avience Biomedicals share price is ₹414 As on 26 June, 2026 | 23:04

The Market Cap of Avience Biomedicals is ₹167.3 Cr As on 26 June, 2026 | 23:04

The P/E ratio of Avience Biomedicals is 23.1 As on 26 June, 2026 | 23:04

The PB ratio of Avience Biomedicals is 7.3 As on 26 June, 2026 | 23:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23